268 related articles for article (PubMed ID: 25593016)
1. A randomized, phase 2 trial of docetaxel with or without PX-866, an irreversible oral phosphatidylinositol 3-kinase inhibitor, in patients with relapsed or metastatic head and neck squamous cell cancer.
Jimeno A; Bauman JE; Weissman C; Adkins D; Schnadig I; Beauregard P; Bowles DW; Spira A; Levy B; Seetharamu N; Hausman D; Walker L; Rudin CM; Shirai K
Oral Oncol; 2015 Apr; 51(4):383-8. PubMed ID: 25593016
[TBL] [Abstract][Full Text] [Related]
2. A randomized, phase II trial of cetuximab with or without PX-866, an irreversible oral phosphatidylinositol 3-kinase inhibitor, in patients with relapsed or metastatic head and neck squamous cell cancer.
Jimeno A; Shirai K; Choi M; Laskin J; Kochenderfer M; Spira A; Cline-Burkhardt V; Winquist E; Hausman D; Walker L; Cohen RB
Ann Oncol; 2015 Mar; 26(3):556-61. PubMed ID: 25524478
[TBL] [Abstract][Full Text] [Related]
3. A randomized, phase 2 trial of Docetaxel with or without PX-866, an irreversible oral phosphatidylinositol 3-kinase inhibitor, in patients with relapsed or metastatic non-small-cell lung cancer.
Levy B; Spira A; Becker D; Evans T; Schnadig I; Camidge DR; Bauman JE; Hausman D; Walker L; Nemunaitis J; Rudin CM; Halmos B; Bowles DW
J Thorac Oncol; 2014 Jul; 9(7):1031-1035. PubMed ID: 24926548
[TBL] [Abstract][Full Text] [Related]
4. A Randomized, Phase II Trial of Cetuximab With or Without PX-866, an Irreversible Oral Phosphatidylinositol 3-Kinase Inhibitor, in Patients With Metastatic Colorectal Carcinoma.
Bowles DW; Kochenderfer M; Cohn A; Sideris L; Nguyen N; Cline-Burkhardt V; Schnadig I; Choi M; Nabell L; Chaudhry A; Ruxer R; Ucar A; Hausman D; Walker L; Spira A; Jimeno A
Clin Colorectal Cancer; 2016 Dec; 15(4):337-344.e2. PubMed ID: 27118441
[TBL] [Abstract][Full Text] [Related]
5. PARTNER: An open-label, randomized, phase 2 study of docetaxel/cisplatin chemotherapy with or without panitumumab as first-line treatment for recurrent or metastatic squamous cell carcinoma of the head and neck.
Wirth LJ; Dakhil S; Kornek G; Axelrod R; Adkins D; Pant S; O'Brien P; Debruyne PR; Oliner KS; Dong J; Murugappan S
Oral Oncol; 2016 Oct; 61():31-40. PubMed ID: 27688102
[TBL] [Abstract][Full Text] [Related]
6. A randomized phase II study of docetaxel with or without vandetanib in recurrent or metastatic squamous cell carcinoma of head and neck (SCCHN).
Limaye S; Riley S; Zhao S; O'Neill A; Posner M; Adkins D; Jaffa Z; Clark J; Haddad R
Oral Oncol; 2013 Aug; 49(8):835-41. PubMed ID: 23727257
[TBL] [Abstract][Full Text] [Related]
7. Phase III randomized, placebo-controlled trial of docetaxel with or without gefitinib in recurrent or metastatic head and neck cancer: an eastern cooperative oncology group trial.
Argiris A; Ghebremichael M; Gilbert J; Lee JW; Sachidanandam K; Kolesar JM; Burtness B; Forastiere AA
J Clin Oncol; 2013 Apr; 31(11):1405-14. PubMed ID: 23460714
[TBL] [Abstract][Full Text] [Related]
8. Docetaxel and cisplatin: an active regimen in patients with locally advanced, recurrent or metastatic squamous cell carcinoma of the head and neck. Results of a phase II study of the EORTC Early Clinical Studies Group.
Schöffski P; Catimel G; Planting AS; Droz JP; Verweij J; Schrijvers D; Gras L; Schrijvers A; Wanders J; Hanauske AR
Ann Oncol; 1999 Jan; 10(1):119-22. PubMed ID: 10076732
[TBL] [Abstract][Full Text] [Related]
9. A phase II trial of the BCL-2 homolog domain 3 mimetic AT-101 in combination with docetaxel for recurrent, locally advanced, or metastatic head and neck cancer.
Swiecicki PL; Bellile E; Sacco AG; Pearson AT; Taylor JM; Jackson TL; Chepeha DB; Spector ME; Shuman A; Malloy K; Moyer J; McKean E; McLean S; Sukari A; Wolf GT; Eisbruch A; Prince M; Bradford C; Carey TE; Wang S; Nör JE; Worden FP
Invest New Drugs; 2016 Aug; 34(4):481-9. PubMed ID: 27225873
[TBL] [Abstract][Full Text] [Related]
10. Cetuximab, docetaxel, and cisplatin as first-line treatment in patients with recurrent or metastatic head and neck squamous cell carcinoma: a multicenter, phase II GORTEC study.
Guigay J; Fayette J; Dillies AF; Sire C; Kerger JN; Tennevet I; Machiels JP; Zanetta S; Pointreau Y; Bozec Le Moal L; Henry S; Schilf A; Bourhis J
Ann Oncol; 2015 Sep; 26(9):1941-1947. PubMed ID: 26109631
[TBL] [Abstract][Full Text] [Related]
11. Phase II trial of everolimus in patients with previously treated recurrent or metastatic head and neck squamous cell carcinoma.
Geiger JL; Bauman JE; Gibson MK; Gooding WE; Varadarajan P; Kotsakis A; Martin D; Gutkind JS; Hedberg ML; Grandis JR; Argiris A
Head Neck; 2016 Dec; 38(12):1759-1764. PubMed ID: 27232378
[TBL] [Abstract][Full Text] [Related]
12. Docetaxel, cisplatin, and fluorouracil for patients with inoperable recurrent or metastatic head and neck squamous cell carcinoma.
Cho H; Nishiike S; Yamamoto Y; Takenaka Y; Nakahara S; Yasui T; Hanamoto A; Inohara H
Auris Nasus Larynx; 2015 Oct; 42(5):396-400. PubMed ID: 25721854
[TBL] [Abstract][Full Text] [Related]
13. Significance of mammalian target of rapamycin in patients with locally advanced stage IV head and neck squamous cell carcinoma receiving induction chemotherapy with docetaxel, cisplatin, and fluorouracil.
Li SH; Lin WC; Huang TL; Chen CH; Chiu TJ; Fang FM; Huang WT; Hsu CM; Luo SD; Lai CC; Su YY; Chuang HC; Chien CY
Head Neck; 2016 Apr; 38 Suppl 1():E844-52. PubMed ID: 25917382
[TBL] [Abstract][Full Text] [Related]
14. A multicenter phase 1 study of PX-866 in combination with docetaxel in patients with advanced solid tumours.
Bowles DW; Ma WW; Senzer N; Brahmer JR; Adjei AA; Davies M; Lazar AJ; Vo A; Peterson S; Walker L; Hausman D; Rudin CM; Jimeno A
Br J Cancer; 2013 Sep; 109(5):1085-92. PubMed ID: 23942080
[TBL] [Abstract][Full Text] [Related]
15. Modified docetaxel, cisplatin and fluorouracil therapy as the first-line treatment for patients with recurrent/metastatic squamous cell carcinoma of the head and neck cancer: a retrospective study.
Demirci NS; Aksoy S; Özdemir NY; Erdem GU; Ozcelik M; Tanrikulu E; Eren T; Bozkaya Y; Sahin S; Başol F; Aslan SA; Zengin N; Güllü İ
Curr Med Res Opin; 2017 Mar; 33(3):401-407. PubMed ID: 27817239
[TBL] [Abstract][Full Text] [Related]
16. Docetaxel, cisplatin, and fluorouracil chemotherapy for metastatic or unresectable locally recurrent anal squamous cell carcinoma (Epitopes-HPV02): a multicentre, single-arm, phase 2 study.
Kim S; François E; André T; Samalin E; Jary M; El Hajbi F; Baba-Hamed N; Pernot S; Kaminsky MC; Bouché O; Desrame J; Zoubir M; Ghiringhelli F; Parzy A; De La Fouchardiere C; Smith D; Deberne M; Spehner L; Badet N; Adotevi O; Anota A; Meurisse A; Vernerey D; Taieb J; Vendrely V; Buecher B; Borg C
Lancet Oncol; 2018 Aug; 19(8):1094-1106. PubMed ID: 30042063
[TBL] [Abstract][Full Text] [Related]
17. A phase II study of temsirolimus and erlotinib in patients with recurrent and/or metastatic, platinum-refractory head and neck squamous cell carcinoma.
Bauman JE; Arias-Pulido H; Lee SJ; Fekrazad MH; Ozawa H; Fertig E; Howard J; Bishop J; Wang H; Olson GT; Spafford MJ; Jones DV; Chung CH
Oral Oncol; 2013 May; 49(5):461-7. PubMed ID: 23384718
[TBL] [Abstract][Full Text] [Related]
18. A phase II study of temsirolimus added to low-dose weekly carboplatin and paclitaxel for patients with recurrent and/or metastatic (R/M) head and neck squamous cell carcinoma (HNSCC).
Dunn LA; Fury MG; Xiao H; Baxi SS; Sherman EJ; Korte S; Pfister C; Haque S; Katabi N; Ho AL; Pfister DG
Ann Oncol; 2017 Oct; 28(10):2533-2538. PubMed ID: 28961834
[TBL] [Abstract][Full Text] [Related]
19. Phase II study of docetaxel and cisplatin in patients with recurrent or disseminated squamous-cell carcinoma of the head and neck.
Specht L; Larsen SK; Hansen HS
Ann Oncol; 2000 Jul; 11(7):845-9. PubMed ID: 10997812
[TBL] [Abstract][Full Text] [Related]
20. Buparlisib and paclitaxel in patients with platinum-pretreated recurrent or metastatic squamous cell carcinoma of the head and neck (BERIL-1): a randomised, double-blind, placebo-controlled phase 2 trial.
Soulières D; Faivre S; Mesía R; Remenár É; Li SH; Karpenko A; Dechaphunkul A; Ochsenreither S; Kiss LA; Lin JC; Nagarkar R; Tamás L; Kim SB; Erfán J; Alyasova A; Kasper S; Barone C; Turri S; Chakravartty A; Chol M; Aimone P; Hirawat S; Licitra L
Lancet Oncol; 2017 Mar; 18(3):323-335. PubMed ID: 28131786
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
